NASDAQ:ALGS Aligos Therapeutics Q2 2026 Earnings Results & Report $4.86 -0.53 (-9.83%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$4.89 +0.03 (+0.62%) As of 10/16/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aligos Therapeutics beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.14 versus the -$1.09 consensus estimate, while revenue of $27.78 million topped the $24.68 million estimate by $3.10 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 6, 2026TimeBefore Market OpensConference Call9:30 AM ET Aligos Therapeutics EPS ResultsActual EPS-$0.14Consensus EPS -$1.09Beat/MissBeat by +$0.95One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersAligos Therapeutics Revenue ResultsActual Revenue$27.78 millionExpected Revenue$24.68 millionBeat/MissBeat by +$3.10 millionYoY Revenue GrowthN/AUpcoming EarningsAligos Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aligos Therapeutics Q2 2026 Earnings FAQ Did Aligos Therapeutics beat earnings estimates for Q2 2026? Aligos Therapeutics (NASDAQ:ALGS) reported earnings of -$0.14 per share for Q2 2026, beating the consensus estimate of -$1.09. The report was announced on Thursday, August 6, 2026. What was Aligos Therapeutics' revenue for Q2 2026? Aligos Therapeutics reported revenue of $27.78 million for Q2 2026, against a consensus estimate of $24.68 million. When is Aligos Therapeutics' next earnings date? Aligos Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Aligos Therapeutics on the company's earnings history page. Aligos Therapeutics Earnings HeadlinesAligos Therapeutics, Inc. (ALGS) - What Are Researchers Saying About This Stock?October 12, 2026 | americanbankingnews.comAligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting 2026October 6, 2026 | marketscreener.comMALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)Aligos Therapeutics To Present HBV, HDV Programs At AASLD 2026October 6, 2026 | rttnews.comAligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026October 5, 2026 | globenewswire.comAligos Therapeutics Amends Long-Term Headquarters Lease AgreementSeptember 15, 2026 | tipranks.comSee More Aligos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aligos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your email. Email Address About Aligos TherapeuticsAligos Therapeutics (NASDAQ:ALGS) is a clinical-stage biopharmaceutical company focused on developing medicines for chronic liver diseases and other viral infections. The company’s research programs are designed to address significant unmet needs in conditions including chronic hepatitis B virus (HBV) infection, hepatitis D virus (HDV) infection and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis. Aligos’ pipeline includes investigational therapies intended to target different stages of disease biology. Its HBV programs include capsid assembly modulators, such as ALG-000184, which are designed to interfere with the virus’s replication cycle. The company has also developed ALG-055009, an oral thyroid hormone receptor beta agonist being evaluated for potential use in MASH. Aligos has pursued additional antiviral research, including programs directed at coronaviruses and other viral diseases. Founded in 2018, Aligos Therapeutics is headquartered in South San Francisco, California. The company conducts research and clinical development through collaborations and clinical studies intended to support the advancement of its investigational medicines in global markets. Its programs remain subject to clinical testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.View Aligos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026)Northrop Grumman (10/20/2026)RTX (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
